European Society of Hypertension

About: European Society of Hypertension is a other organization based out in Milan, Italy. It is known for research contribution in the topics: Blood pressure & Ambulatory blood pressure. The organization has 146 authors who have published 167 publications receiving 20150 citations.

Aldosterone Predicts Cardiovascular, Renal, and Metabolic Disease in the General Community: A 4‐Year Follow‐Up

Abstract: Background We recently reported that normal aldosterone levels are associated with cardiovascular, renal, and metabolic disease in a sample of the US general community (Visit 1). For the current analyses we used the same cohort in a new 4‐year follow‐up study (Visit 2). Methods and Results We measured aldosterone at Visit 1 and analyzed its predictive role for new diseases at Visit 2 (n=1140). We measured aldosterone at Visit 2 and investigated its associations with disease at Visit 2 (n=1368). We analyzed aldosterone continuously and we also dichotomized the variable as whether subjects were in the third tertile versus second and first tertiles. As continuous variable at Visit 1, aldosterone predicted new onset hypertension (HTN) (OR=1.36, CI=1.13–1.63, P =0.001), central obesity (OR=1.36, CI=1.07–1.73, P =0.011), and use of lipid‐lowering drugs (OR=1.25, CI=1.05–1.48, P =0.012) at Visit 2, after adjustment for age, sex, and body mass index. When in the third tertile (8.5–88.6 ng/dL), aldosterone predicted type 2 diabetes (T2DM, OR=1.96, CI=1.03–3.70, P =0.039). At Visit 2, aldosterone remained associated with HTN, obesity, and chronic kidney disease (CKD), as reported for Visit 1. However, aldosterone was not associated with heart failure (HF) at Visit 1 and 2, nor was aldosterone a predictor of HF between visits. Conclusions Aldosterone predicts new HTN, central obesity, T2DM, and use of lipid‐lowering drugs in the general community and remains associated with HTN, obesity, and CKD over 4 years. Aldosterone is not associated nor predicts HF. Further studies are warranted to evaluate aldosterone as therapeutic target in the general community.

Relationship of a Body Shape Index and Body Roundness Index with carotid atherosclerosis in arterial hypertension

Abstract: Background and aims A Body Shape Index (ABSI) and Body Roundness Index (BRI) are two new anthropometric adiposity indices that have shown to be associated better than BMI with adipose abdominal tissue, with the onset of diabetes and the risk of premature death. Little is known about the influence of ABSI and BRI on subclinical vascular damage. The study was aimed to assess the relationship between ABSI and BRI with carotid atherosclerosis damage in subjects with arterial hypertension. Methods and results A total of 468 patients with arterial hypertension (30–80 years old) were enrolled; adiposity indices were calculated (BMI, WC, ABSI, BRI) and carotid ultrasonographic examination was performed to detect atherosclerotic damage (IMT or atherosclerotic plaque). BRI, but not ABSI, was higher in subjects with IMT> 0.90 mm in comparison to those with a lower IMT (p Conclusions ABSI may be proposed as a better correlate of carotid atherosclerosis than the traditional measures of adiposity.

Hypertensive heart disease and obesity: a complex interaction between hemodynamic and not hemodynamic factors.

Abstract: The worldwide prevalence of obesity has nearly doubled, with an increase in obesity-related cardiovascular disease and mortality. Several factors are involved in the genesis of hypertension and hypertensive heart disease (HHD) in overweight/obesity. This review is focused on bridging factors between excessive adiposity and HHD, presenting a unifying hypothesis of vascular–metabolic syndrome, where an “handicap” of the natriuretic peptide system has a central role both in adipocyte dysmetabolism as well as in increased blood pressure and HHD.

Pharmacological Approach to Smoking Cessation: An Updated Review for Daily Clinical Practice

Abstract: Tobacco use is one of the major public health concerns and it is the most preventable cause of morbidity and mortality worldwide Smoking cessation reduces subsequent cardiovascular events and mortality Smoking is a real chronic disorder characterized by the development of an addiction status mainly due to nicotine This condition makes the smokers generally unable to quit smoking without help Different strategies are available to treat smoking dependence that include both non-pharmacological (behavioral counselling) and pharmacological therapies Currently, it is well accepted that smoking cessation drugs are effective and safe in real-world settings Nicotine replacement therapy (NRT), varenicline, bupropion and cytisine are the main pharmacological strategies available for smoking cessation Their efficacy and safety have been proved even in patients with chronic cardiovascular disease Each of these drugs has peculiar characteristics and the clinician should customize the smoking cessation strategy based on currently available scientific evidence and patient's preference, paying particular attention to those patients having specific cardiovascular and psychiatric comorbidities The present document aims to summarize the current viable pharmacological strategies for smoking cessation, also discussing the controversial issue regarding the use of alternative tobacco products, in order to provide useful practical indications to all physicians, mainly to those involved in cardiovascular prevention